INTRODUCTION: Bacterial lipopolysaccharide (LPS) injection prior to hypoxia-ischaemia significantly increases hypoxia-ischaemic brain injury in 7-day-old (P7) rats. In addition, therapeutic hypothermia (HT) is not neuroprotective in this setting. However, the mechanistic aspects of this therapeutic failure have yet to be elucidated. This study was designed to investigate the underlying cellular mechanisms in this double-hit model of infection-sensitised hypoxia-ischaemic brain injury. MATERIAL AND METHODS: P7 rat pups were injected with either vehicle or LPS, and after a 4-hour delay were exposed to left carotid ligation followed by global hypoxia inducing a unilateral stroke-like hypoxia-ischaemic injury. Pups were randomised to the following treatments: (1) vehicle-treated pups receiving normothermia treatment (NT) (Veh-NT; n = 40), (2) LPS-treated pups receiving NT treatment (LPS-NT; n = 40), (3) vehicle-treated pups receiving HT treatment (Veh-HT; n = 38) and (4) LPS-treated pups receiving HT treatment (LPS-HT; n = 35). On postnatal day 8 or 14, Western blot analysis or immunohistochemistry was performed to examine neuronal death, apoptosis, astrogliosis and microglial activation. RESULTS: LPS sensitisation prior to hypoxia-ischaemia significantly exacerbated apoptotic neuronal loss. NeuN, a neuronal biomarker, was significantly reduced in the LPS-NT and LPS-HT groups (p = 0.008). Caspase-3 activation was significantly increased in the LPS-sensitised groups (p < 0.001). Additionally, a significant increase in astrogliosis (glial fibrillary acidic expression, p < 0.001) was seen, as well as a trend towards increased microglial activation (Iba 1 expression, p = 0.051) in LPS-sensitised animals. Treatment with HT did not counteract these changes. CONCLUSION: LPS-sensitised hypoxia-ischaemic brain injury in newborn rats is mediated through neuronal death, apoptosis, astrogliosis and microglial activation. In this double-hit model, treatment with HT does not ameliorate these changes.
INTRODUCTION: Bacterial lipopolysaccharide (LPS) injection prior to hypoxia-ischaemia significantly increases hypoxia-ischaemic brain injury in 7-day-old (P7) rats. In addition, therapeutic hypothermia (HT) is not neuroprotective in this setting. However, the mechanistic aspects of this therapeutic failure have yet to be elucidated. This study was designed to investigate the underlying cellular mechanisms in this double-hit model of infection-sensitised hypoxia-ischaemic brain injury. MATERIAL AND METHODS: P7 rat pups were injected with either vehicle or LPS, and after a 4-hour delay were exposed to left carotid ligation followed by global hypoxia inducing a unilateral stroke-like hypoxia-ischaemic injury. Pups were randomised to the following treatments: (1) vehicle-treated pups receiving normothermia treatment (NT) (Veh-NT; n = 40), (2) LPS-treated pups receiving NT treatment (LPS-NT; n = 40), (3) vehicle-treated pups receiving HT treatment (Veh-HT; n = 38) and (4) LPS-treated pups receiving HT treatment (LPS-HT; n = 35). On postnatal day 8 or 14, Western blot analysis or immunohistochemistry was performed to examine neuronal death, apoptosis, astrogliosis and microglial activation. RESULTS:LPS sensitisation prior to hypoxia-ischaemia significantly exacerbated apoptotic neuronal loss. NeuN, a neuronal biomarker, was significantly reduced in the LPS-NT and LPS-HT groups (p = 0.008). Caspase-3 activation was significantly increased in the LPS-sensitised groups (p < 0.001). Additionally, a significant increase in astrogliosis (glial fibrillary acidic expression, p < 0.001) was seen, as well as a trend towards increased microglial activation (Iba 1 expression, p = 0.051) in LPS-sensitised animals. Treatment with HT did not counteract these changes. CONCLUSION:LPS-sensitised hypoxia-ischaemic brain injury in newborn rats is mediated through neuronal death, apoptosis, astrogliosis and microglial activation. In this double-hit model, treatment with HT does not ameliorate these changes.
Authors: Brian H Kim; Mariano Guardia Clausi; Michelle Frondelli; Israel C Nnah; Chaitali Saqcena; Radek Dobrowolski; Steven W Levison Journal: Dev Neurosci Date: 2017-06-20 Impact factor: 2.984
Authors: Thomas Wood; Catherine Hobbs; Mari Falck; Anne Charlotte Brun; Else Marit Løberg; Marianne Thoresen Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756
Authors: Thomas Wood; Daniel Moralejo; Kylie Corry; Jessica M Snyder; Christopher Traudt; Chad Curtis; Elizabeth Nance; Pratik Parikh; Sandra E Juul Journal: Dev Neurosci Date: 2019-05-10 Impact factor: 2.984
Authors: Kathryn A Martinello; Christopher Meehan; Adnan Avdic-Belltheus; Ingran Lingam; Tatenda Mutshiya; Qin Yang; Mustafa Ali Akin; David Price; Magdalena Sokolska; Alan Bainbridge; Mariya Hristova; Ilias Tachtsidis; Cally J Tann; Donald Peebles; Henrik Hagberg; Tim G A M Wolfs; Nigel Klein; Boris W Kramer; Bobbi Fleiss; Pierre Gressens; Xavier Golay; Nicola J Robertson Journal: Pediatr Res Date: 2021-05-28 Impact factor: 3.953
Authors: Thomas R Wood; Julia K Gundersen; Mari Falck; Elke Maes; Damjan Osredkar; Else Marit Løberg; Hemmen Sabir; Lars Walløe; Marianne Thoresen Journal: Sci Rep Date: 2020-07-02 Impact factor: 4.379
Authors: Kathryn A Martinello; Christopher Meehan; Adnan Avdic-Belltheus; Ingran Lingam; Sara Ragab; Mariya Hristova; Cally J Tann; Donald Peebles; Henrik Hagberg; Tim G A M Wolfs; Nigel Klein; Ilias Tachtsidis; Xavier Golay; Boris W Kramer; Bobbi Fleiss; Pierre Gressens; Nicola J Robertson Journal: Sci Rep Date: 2019-07-15 Impact factor: 4.379